

Enamine and Pohang Accelerator Laboratory Partner to Speed Up Fragment-Based Discovery Projects

KYIV, UKRAINE, April 30, 2025 /EINPresswire.com/ -- Enamine, the leading provider of chemical compounds and drug discovery services, and Pohang Accelerator Laboratory (PAL), a science and technology institution in South Korea, have signed a Memorandum of Understanding (MOU) to advance collaborative drug discovery efforts. The memorandum outlines a joint commitment to pursue research and development in fragment-based drug discovery and hit optimization. Both parties aim to provide a streamlined path from fragment identification to advanced leads by combining advanced screening technologies with fast-track chemical development.



Enamine will provide access to its

comprehensive and easy-to-follow fragment library. The company will also lead hit development, supplying hit analogues from its vast make-on-demand chemical space: Enamine REAL and Enamine MADE, and offering follow-up chemistry and biology services, including molecular screening, compound profiling, and animal studies.

PAL will integrate Enamine fragment libraries into its Crystallographic Fragment Screening platform at its synchrotron radiation facility. This facility will be used to identify fragment hits that serve as starting points for collaborative drug discovery projects. By combining resources and technical platforms, Enamine and PAL intend to enhance the speed and quality of fragment-based lead generation. This collaboration is designed to support pharmaceutical companies and academic research institutions across Korea and the broader Asian region.

In addition to the scientific collaboration, the parties will engage in co-advertising and comarketing efforts to promote Crystallographic Fragment Screening. These initiatives are expected to expand access to high-performance discovery tools and encourage broader uptake of the platform among researchers.

Organisation with unique partnering opportunities in exploring new chemical space. The company combines access to the in-house produced screening compounds (4.5M in stock) and building blocks (350K in stock) with a comprehensive platform of integrated discovery services to advance and accelerate the efforts in Drug Discovery. For more information, visit: https://enamine.net

feasible molecules that can be synthesized at Enamine extremely fast (3-4 weeks), with high feasibility (over 80%), and inexpensive. The REAL Compounds are created by parallel chemistry through the compilation of 143,000 in-stock building blocks via 167 well-validated parallel synthesis protocols, underlying Enamine's approach to design make-on-demand compounds to maximize synthesis success rate.

efforts. For more information, visit: https://pal.postech.ac.kr

laroslava Kos Enamine Ltd. email us here

This press release can be viewed online at: https://www.einpresswire.com/article/807669133

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2025 Newsmatics Inc. All Right Reserved.